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ABSTRACT 
Previous studies have suggested that at least some of the behavioral effects of heroin might be 
mediated by its active metabolite 6-acetylmorphine (6-AM).  The aim of the present study was to 
investigate the reinforcing effects of 6-AM and its role in mediating those of heroin.  We used an 
intravenous self-administration procedure in male Sprague-Dawley rats including four phases: 
acquisition, extinction, relapse into drug-seeking, and re-acquisition. Animals learned to self-
administer 0.135 µmol/kg (44.3 μg/kg) 6-AM at similar rates as an equimolar dose (50 μg/kg) heroin 
under fixed ratio 1 (FR1), but a significantly higher rates under FR2. No differences were observed 
during extinction. Priming with 0.068 µmol/kg reinstated lever presses for both drugs during the first 
hour of the relapse session. Re-acquisition of self-administration with the dose used during 
acquisition (0.135 µmol/kg) restored lever presses for both drugs at a level similar to the last 
acquisition session. However, re-acquisition using half the dose (0.068 µmol/kg) significantly 
increased self-administration in animals receiving 6-AM, but not in animals receiving heroin. 
Administration of a specific monoclonal antibody against 6-AM before the relapse session blocked 
relapse of self-administration of 6-AM and affected later re-acquisition in a manner compatible with 
a shift to the right of the dose-effect curve. Only minor effects of the antibody were observed on the 
reinstatement of heroin-seeking (relapse) and on the re-acquisition of heroin self-administration. The 
present results show that intravenous 6-AM possesses similar reinforcing properties as heroin. 
However, some observed disparities also indicate some differences in their rewarding qualities after 
systemic administration. The lack of effect of the 6-AM antibody over relapse and re- acquisition of 
heroin self-administration calls for further studies to clarify the role of heroin and its metabolites in 
heroin reward.   
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1. INTRODUCTION 
Heroin (diacetylmorphine) is an acetylated derivative of morphine with a high addiction potential, 
higher than for any other substance, except tobacco (Darke, 2011; Nutt et al., 2007).  The past few 
years in particular have seen a sharp increase in heroin abuse and, as a consequence, an alarming 
rise in the number of heroin-related overdoses and deaths (Dowell et al., 2017; European Monitoring 
Centre for Drugs and Drug Addiction, 2018).  Yet, despite decades of research on its 
pharmacodynamics and pharmacokinetics, the mechanisms responsible for the reinforcing effects of 
heroin, the basis of its high abuse potential, are still poorly understood.   
Heroin’s estimated plasma half-life is less than 5 minutes, being rapidly transformed into 6-
acetylmorphine (6-AM), which is further de-acetylated to morphine, both in rodents (Andersen et al., 
2009; Gottas et al., 2013) and in humans (Rook et al., 2006a; Rook et al., 2006b).  Heroin, 6-AM, and 
morphine are all µ-opioid (MOP) receptor agonists (Inturrisi et al. 1983, Selley et al. 2001).  The very 
fast metabolism of heroin, and their very similar pharmacological profiles,  led to hypothesize that 
the effects of heroin are mostly mediated by morphine (Way et al., 1960; Wright, 1941).  However, 
there is some evidence against this simplification.  The euphorigenic effect of heroin (the so-called 
‘rush’ or ‘high’) develops very rapidly after systemic administration (Smith and Beecher, 1962), 
whereas morphine concentrations in the plasma increase much more slowly (Rook et al., 2006a; 
Rook et al., 2006b), and, owing to its low lipophilicity, even more slowly in the brain, (Gottas et al., 
2014; Seleman et al., 2014).   Thus, the attention of researchers has shifted to 6-AM, which binds 
MOP receptors with the same affinity of morphine (Inturrisi et al., 1983) but has greater efficacy 
(Selley et al., 2001).  In humans, 6-AM is found at higher concentrations than morphine immediately 
after heroin administration, overlapping in time with heroin’s ‘high’ (Rook et al., 2006a; Rook et al., 
2006b).  In rodents as well, 6-AM represents the main metabolites for the first 30 min after heroin 
administration (Andersen et al., 2009; Gottas et al., 2014; Gottas et al., 2013). Thus, 6-AM is a clear 
candidate to convey the reinforcing properties of systemic heroin.    
It has been shown that systemic administration of 6-AM can produce analgesia and constipation 
(Umans and Inturrisi, 1981), as well as psychomotor activation (Andersen et al., 2009) similar to that 
produced by heroin.  Interestingly, the time-course of striatal concentration of 6-AM parallel those of 
locomotor activity (Andersen et al., 2009) and striatal dopamine levels (Gottas et al., 2014) after 
heroin administration.  Still, relatively little is known about the rewarding properties of 6-AM.  Thus, 
the main aim of the present study was to compare the reinforcing effects of equimolar doses of 6-
AM and heroin using an intravenous (i.v.) self-administration procedure in the rat.  The second goal 
was to assess the effects of a pretreatment with a specific monoclonal antibody (mAb) raised against 
6-AM (Bogen et al., 2014; Kvello et al., 2016) on the reinforcing effects of heroin, and in particular on 
its ability to affect reinstatement of drug-seeking in animal model of relapse (for a review, see 
Shaham et al. 2003) and to sustain self-administration. 
  
2. MATERIAL AND METHODS 
2.1 Animals 
A total of 89 male Sprague-Dawley rats (ENVIGO, Huntingdon, United Kingdom) weighting 250-275 gr 
at the beginning of the experiment were used in this study. Rats were housed in a temperature- and 
  
humidity-controlled room (21 ±1° C and 55 ± 5%, respectively) on a 12/12 h reverse light cycle (lights 
off at 8:00 am) for the entire duration of the experiments. Upon arrival, rats were housed in triplets 
in grid-top plastic cages (52 cm length, 40 cm width and 27 cm height) with wood shavings bedding 
and brown paper nesting material and allowed to acclimatize to the animal facility for a week. After 
this period, the animals underwent i.v. catheterization surgery. Eleven to sixteen animals were tested 
simultaneously, representing the different treatment groups, during one entire self-administration 
procedure lasting 17 days, with one session per day. The rats had ad libitum access to food and water 
throughout the experiment, except during the self-administration sessions. All experimental 
procedures on animals were conducted in accordance with UK Animals (Scientific Procedures) Act 
1986 (www.legislation.gov.uk/ukpga/1986/14/contents). 
2.2 Surgery 
On the day of surgery, the rats received an intraperitoneal injection of 2mg/kg of xylazine 
hydrochloride (Rompun, Bayer HealthCare) and 100mg/kg of ketamine (Anesketin, Dechra). The 
surgical procedures were similar to those previously described by (Caprioli et al., 2008). Briefly, an  
11 cm silicone catheter (0.37-mm inner diameter and 0.94-mm outer diameter), sheathed at 3.4 cm 
from its proximal end by a silicone bead, was inserted into the right jugular vein and secured to the 
surrounding soft tissues with silk thread. Its distal end was externalized through a small incision at 
the nape of the neck and connected to an L-shaped 22-gauge cannula, which was secured to rat's 
skull using dental cement and stainless steel screws. The catheters were flushed daily (at 6 pm) with 
0.1 ml of sterile saline. Immediately after surgery, rats were assigned to the heroin or 6-AM group 
and individually housed in the self-administration chamber, where they remained for the rest of the 
experiment. The rats were allowed to recover from the surgery for 7–10 days before starting self-
administration training. 
2.3 Apparatus 
The apparatus, previously described in detail by Caprioli et al. (2007), consisted of self-administration 
chambers (28.5-cm length, 27-cm width and 32-cm height) made of transparent plastic (front and 
rear walls), aluminium (sidewalls and ceiling) and stainless steel (grid floor).  Plastic trays covered 
with pinewood shaving were placed under the cage floors.  Each cage was equipped with a 
counterbalanced arm holding a liquid swivel and two retractable levers, positioned 12.5 cm apart and 
9 cm above the floor on the left-hand wall.  Cue lights consisting of either a set of triple (green, red 
and yellow) LED lights were positioned above each of two levers.  The self-administration cages were 
placed within sound-attenuating and light-attenuating cubicles.  Each cage was connected via an 
electronic interface to a syringe pump (Razel Scientific Instruments, St. Albans, VT, USA) and to a 
programmable logic controller (PLC; Allen Bradley, Milwaukee, WI, USA).  Finally, the PLCs were 
connected to PCs running custom control software developed by Aries Sistemi S.r.l. (Rome, Italy). 
2.4 Drugs 
Heroin hydrochloride (Johnson Matthey-Macfarlan Smith, Edinburgh, UK) and 6-AM hydrochloride 
(Lipomed, Arlesheim, Switzerland) were dissolved in saline.  Equimolar doses of heroin and 6-AM, an 
infusion volume of 40 µl, and an infusion time of 4 s, were used throughout the experiment.  During 
the acquisition phase (see Section 2.5.1), a unit dose of 0.135 µmol/kg (corresponding to 50 μg/kg of 
heroin and to 44.3 μg/kg of 6-AM) was used.  These doses were selected on the basis of previous 
studies (Caprioli et al. 2008; Montanari et al. 2015).  The priming doses for the relapse session (see 
  
Section 2.5.3) were 0.017, 0.034, or 0.068 µmol/kg (2.5, 12.5 or 25 μg/kg for heroin and 2.21, 11.1 or 
22.2 μg/kg for 6-AM, respectively).  The priming doses were selected based on a study showing that 
25 μg/kg of heroin was a more effective priming dose than 50 or 100 μg/kg for inducing relapse into 
heroin-seeking (Montanari et al. 2015).  Two doses, 0.068 or 0.135 µmol/kg (equivalent to 25 and 50 
μg/kg for heroin, and 22.15 and 44.3 μg/kg for 6-AM, respectively), were used for the re-instatement 
sessions (see Section 2.5.4).   
2.5 Self-administration procedure 
Figure 1 illustrates the timeline of the experimental protocol.   
Prior to the beginning of each session food, water and nesting material were removed from the self-
administration chamber and infusion lines were sterilized with ethanol, flushed with sterile saline, 
and then loaded with the appropriate drug solutions.  At the beginning of each session, the two 
levers were extended (one ‘active’ and one ‘inactive’, counterbalanced for the right vs. left position) 
and the cue light (all three LEDs) above the active lever was switched on.  The schedule requirement, 
the number of consecutive lever presses, to obtain an infusion was increased from fixed ratio 1 (FR1) 
during the first 5 sessions, to FR2 for the rest of the experiment.  Each animal received the same 
drug, 6-AM or heroin, through all the experiment.  All sessions lasted 6 hours, and the animals were 
housed in the self-administrations chambers for all the length of the experiment.  
2.5.1 Acquisition 
The rats were trained to self-administer 0.135 µmol/kg 6-AM or heroin during 7 consecutive daily 
sessions.  After pressing the active lever at the programmed schedule, a drug infusion was delivered, 
the levers retracted, and the cue light switched off for a 40-s timeout period (to prevent self-
administration of multiple consecutive infusions and overdosing).  The rats that did not 
spontaneously self-administer at least one infusion within the first 5 min of the session were placed 
with their forepaws on the lever to prime an infusion. This was repeated at times 60 and 120 min for 
rats that did not self-administer at least one infusion in the time periods 5–60 and 60–120 min. These 
priming infusions were not included in the data analysis 
2.5.2 Extinction 
The extinction phase consisted of 7 consecutive daily sessions (sessions 8 to 14), during which the 
rats received, upon completion of the task (FR2), an i.v. saline infusion instead of the drug solution. 
All other conditions during the sessions were kept identical. No priming infusions were given during 
extinction.  
At the end of session 14, the rats were administered either an intraperitoneal injection of 10 mg/kg 
of a human mAb raised against 6-AM (Bogen et al., 2014; Moghaddam et al., 2003) or an equivalent 
volume of saline and left undisturbed in their cages.  
2.5.3 Re-instatement of drug-seeking (relapse session) 
Before the beginning of the session (session 15), the infusion lines were backfilled with 50 μl of 
sterile saline containing one of the priming doses (0.017, 0.034, or 0.068 µmol/kg) of 6-AM or heroin. 
The rest of the infusion lines were filled with sterile saline.  At the beginning of the session, a 10 -s, 
100-μl infusion (consisting of 50 µl of the reinstatement dose followed by 50 µl saline solution) was 
  
triggered. During the rest of the session, lever pressing of the active lever resulted in the self-
administration of saline, as during the extinction sessions.  
2.5.4 Re-acquisition of self-administration 
During sessions 16 and 17 the rats were returned to a schedule of self-administration identical to 
that of sessions 6 and 7 (i.e., on an FR2 schedule of reinforcement), with the difference that on one 
session they received the dose used during training (0.135 µmol/kg) and on the other one half this 
dose (0.068 µmol/kg), in a counterbalanced fashion.  
2.6 Quantification of IgG1. 
At the end of session 17, the rats were sacrificed with an i.v. infusion of pentobarbital (4 mg in 20 μl), 
which also served to assess catheter patency.  The animals that did not become ataxic and died 
within 5 seconds (a total of 7 rats) were excluded from the data analysis.  After cervical dislocation 
and death confirmation, blood samples were taken by cardiac puncture with a heparinized syringe 
and put in 0.5 ml low protein binding Eppendorf tubes held in ice.  The tubes were then stored in a -
80°C freezer and later shipped to Oslo University Hospital (Oslo, Norway) for quantification of blood 
IgG1 levels. 
Blood samples were diluted and analyzed for human IgG1 using a Novex ELISA kit (Thermo Fisher 
Scientific Inc., Waltham, MA).  Two duplicates of each standard and control were used. Absorbance 
was measured (450 nm) within 1 hour of adding the stop solution using an ELx808 Absorbance 
Microplate Reader (BioTek Instruments Inc., Winooski, VT).  All animals receiving the 6-AM mAb were 
tested, but only 11 animals pretreated with saline was analysed as control. 
2.7 Data analysis 
Self-administration and extinction data were analysed using a two-way mixed ANOVA for the 
between-subject factor drug (two levels: heroin vs. 6-AM) and the within-subject factor session (one 
level for each session).  Sessions 1-5 (on FR1) and 6-7 (on FR2) were analysed separately. Relapse was 
defined as a significant increase on the number of presses on the active lever and/or in the number 
of infusions during the first hour of session 15 relative to the first hour of the last extinction session 
(session 14).  Relapse data were analyzed using a three-way mixed ANOVA for the between-subject 
factors drug (two levels: heroin vs. 6-AM) and antibody (saline vs. mAb) and the between-subject 
factor relapse (two levels: session 14 vs. session 15).  Re-acquisition of self-administration was 
indicated by a significant increase in the number of presses on the active lever and/or in the number 
of infusions during session 16 or 17 relative to the last extinction session (session 14).  Re-acquisition 
data were analysed using a four-way mixed ANOVA for the between-subject factors drug (two levels: 
heroin vs. 6-AM), dose (two levels: 0.068 vs 0.135 µmol/kg) and antibody (saline vs. mAb) and the 
between-subject factor re-acquisition (two levels: session 14 vs. session 16 or 17).  Student’s t-tests 
for independent or repeated measures were used, as required, for post-hoc comparisons of interest.  
The statistical analysis was run separately for active lever presses, inactive lever presses, and drug 
infusions. All statistical analyses were conducted using SPSS statistical software version 23 (IBM Corp, 
Armonk, NY, USA). 
3. RESULTS 
3.1 Acquisition (Figure 2) 
  
During sessions 1-5, animals learned to self-administer 6-AM or heroin (on FR1), as indicated by a 
significant increase in lever presses over session (Session: F4,320=43.98, p<0.0001), with no significant 
effect of drugs (Session x Drug:  F4,320=1.94, p=0.104; Drug: F1,80=2.83, p=0.096).  Also for sessions 6-7 
(on FR2) there was a significant effect of session (F1,80=138.53, p<0.0001), but in this case also a 
significant effect of drug (F1,80=4.70, p=0.033) and a drug x session interaction (F1,80=4.53, p=0.036), 
as lever pressing for 6-AM was greater than for heroin.  The same pattern was observed for the 
number of infusions. 
3.2 Extinction (Figure 2) 
During the extinction sessions, there was a significant decrease in the number of presses on the 
active lever (F6,480=17.87, p≤0.0001) with no main effect of drug (F1,80=0.39, p=0.843) nor session x 
drug interaction (F6,480=0.779, p=0.527).  The same pattern was observed for the number of saline 
infusions.  
3.3 Relapse into drug-seeking (Figure 3) 
Since priming with 0.017 or 0.034 µmol/kg 6-AM or heroin did not induce relapse (data not shown), 
the use of these doses was stopped and only the dose of 0.068 µmol/kg was used for priming during 
the rest of the experiment. Due to the low number of animals for these doses (total n=16 and 21 for 
each dose, respectively) within each level of the treatment factors (heroin vs 6-AM and saline vs 
mAb), no statistical analysis was carried out. 
Priming with 0.068 µmol/kg reinstated lever pressing on the drug-paired lever (Relapse: F1,41=18.11, 
p=0.000) and the number of infusions (Relapse: F1,41=17.70, p=0.000) during the first hour after 
priming, without affecting presses at the inactive lever (data not shown). The post-hoc tests showed 
that priming with both drugs reestablished self-administration in the saline pretreated animals, but 
in the animals pretreated with the 6-AM mAb only the group receiving heroin showed relapse. 
3.4 Re-acquisition of self-administration (Figure 4) 
When the drugs were made available for the re-acquisition of self-administration on sessions 16 and 
17, there was a significant effect in the number of active lever presses (F1,74=89,52, p<0.0001) and in 
the number of infusions (F1,74=85,05, p<0.0001) relative to last extinction session (session 14).  This 
effect  was depending on which drug animals received, which dose, as well as pretreatment with the 
6-AM antibody, both for the number of presses at the active lever (re-acquisition x drug x dose x 
pretreatment :  F1,74=9,45, p=0.003) and number of infusions (re-acquisition x drug x dose x 
pretreatment :  F1,74=8,08, p=0.004).  
Post-hoc analysis showed that the rats pre-treated with saline resumed lever pressing on the active 
lever and received a number of infusions significantly greater than on the last extinction session and 
at least similar to those of the last session of acquisition (session 7), independently of the drug or 
dose received. However, the animals receiving 0.068 µmol/kg 6-AM exhibited even a nearly 
statistical significant (p=0.065) higher number of presses on the active lever and a significant (p<0.05) 
higher number of infusions than observed on the last acquisition session.  
In the animals pretreated with the 6-AM mAb, the effects differed depending on the drug and dose 
received. In those animals  receiving 0.068 µmol/kg 6-AM and pretreated with the 6-AM mAb, the 
number of active lever presses and infusions received were not significant different either from the 
  
performance on the last acquisition day or from the last day of extinction. On the contrary, the 
animals pretreated with the mAb and receiving  0.135 µmol/kg 6-AM showed a significant (p<0.05) 
increase in the number of presses at the active lever and the number of infusions, not only compared 
against saline pretreatment, but also compared against the performance observed during the last 
day of acquisition. Pretreatment with the 6-AM mAb did not affect the re-acquisition of self-
administration of heroin compared with the saline pretreated animals. However, the number of 
infusions were statistically significant higher (p<0.05) compared to the last acquisition day in the 
animals receiving 0.135 µmol/kg heroin, despite the effect size being small. There were not observed 
any significant effect on the number of presses on the inactive lever during the re-acquisition phase. 
No significant differences between saline and 6-AM mAb pretreatment were observed during the 
second day of re-acquisition for any of the two drugs and doses used (data not shown). 
3.5 IgG levels 
As expected, IgG levels were significantly (p<0.001) higher in animals pretreated with 6-AM mAb 
(35.2 ±2.8 µg/ml) compared with animals pretreated with saline (0.18 ±0.09 µg/ml). No differences 
were observed in IgG levels between animals self-administering 6-AM or heroin (33.3 ±3.5 µg/ml and 
35.2 ±2.8 µg/ml , respectively). 
 
4. DISCUSSION  
The present study shows that 6-AM has powerful reinforcing effects, as indicated by its ability to 
sustain i.v. self-administration in the rat.  The rats that had acquired 6-AM self-administration also 
exhibited relapse into drug-seeking when primed with a single infusion after a period of abstinence 
and then rapidly resumed self-administration behavior when given access to 6-AM again. This is, to 
the best of our knowledge, the first report to demonstrate the reinforcing effects of 6-AM in a self-
administration procedure, considered the standard animal model for drug addiction (Spanagel, 
2017).   
4.1 Reinforcing effects of 6-AM vs. heroin 
The reinforcing effects of 6-AM were similar to those of heroin, including the ability to trigger relapse 
into drug-seeking after a period of abstinence.  However, the patterns of self-administration for 6-
AM presented interesting differences from that of heroin.  Although during the acquisition phase 
there were not statistical differences in the rate of responding on FR1, there was a significantly 
higher rate and greater number of infusions for 6-AM versus heroin on FR2.  Furthermore, during the 
re-acquisition phase, the response rate and number of infusions for rats self-administering 0.068 
µmol/kg of 6-AM was nearly twice as high as that of rats self-administering 0.135 µmol/kg (the dose 
used during the acquisition phase).  On the contrary, the response rate and number of infusions for 
the two heroin doses did not differ from each other.  These data seem to suggest that when 
administered systemically 6-AM is not only more potent than heroin with regard to its reinforcing 
effects but it also has greater efficacy.   
4.2. Role of 6-AM in the reinforcing effects of heroin 
The ability of 6-AM to sustain self-administration is consistent with the notion that 6-AM might 
represent the main mediator of the reinforcing effects of heroin.  Raleigh and colleagues (Raleigh et 
  
al., 2014), for example, in reporting that a morphine-conjugated vaccine can alter heroin self-
administration in the rat, attributed this effect mainly to a reduction in brain levels of 6-AM.  Thus, 
we hypothesized that a pre-treatment with specific mAb against 6-AM would block, or at least 
impair, heroin self-administration.  Yet, we found that while mAb was effective in blocking 6-AM-
induced relapse of drug seeking and altered the re-acquisition of 6-AM self-administration (in a way 
compatible with a shift to the right in the dose-effect curve), it had a negligible effect on heroin-
induced relapse and on the re-acquisition of heroin self-administration, even though at the end of 
the experiment there were no differences in IgG levels between 6-AM and heroin groups. 
This finding does not appear to be consistent with the hypothesized role of 6-AM in the reinforcing 
effects of heroin.  In a preliminary experiment conducted in preparation for the present study (data 
not shown), an intraperitoneal injection of 7.5 mg/kg of mAb 15 min before an i.v. infusion of 0.135 
µmol/kg of heroin reduced brain levels of 6-AM by 30-50% (measured 5 min after heroin 
administration).  Previous experiments have shown that, after heroin administration in mice, this 
mAb against 6-AM is able to reduce 6-AM levels in the brain, accompanied by decreases in the 
heroin-induced psychomotor activity (Bogen et al., 2014; Kvello et al., 2016). In a recent study, this 
mAb was able to block the conditioned place preference (CPP) induced by heroin in mice (Kvello et 
al., Submitted), indicating that blockade of 6-AM is able to affect at least some aspects of the 
rewarding properties of heroin.  Thus, the lack of effect of the mAb on heroin self-administration 
cannot be attributed to a possible general lack of action on 6-AM generated by heroin.   
There are possible reasons why anti-6-AM mAb failed to affect heroin self-administration and heroin 
priming.  The first one concerns the kinetics of heroin deacetylation. Most of the 6-AM found in the 
brain shortly after heroin administration originates from heroin deacetylation in the blood (Boix et 
al., 2013).  Still, 6-AM levels in the brain are much higher and rise faster after administration of 
heroin than after administration of equimolar doses of 6-AM (Andersen et al., 2009; Gottas et al., 
2014).  This ‘additional’ amount of 6-AM most likely derives from the deacetylation of heroin in the 
brain after its rapid passage through the blood-brain barrier (Oldendorf et al., 1972) and is obviously 
out of the reach of the mAb.  Indeed, brain 6-AM levels in the brain are reduced by mAb to a lesser 
extent after heroin administration than after 6-AM administration (Kvello et al., 2016). The mAb is 
also much less effective in reducing heroin-induced behavior immediately after heroin administration 
than later in time (i.e figure 3 in (Bogen et al., 2014)).  Thus, the rapid intracerebral formation of 6-
AM from heroin could be fast enough to sustain self-administration at the infusion dose used (Comer 
et al., 1999; Marsch et al., 2001; Samaha and Robinson, 2005) and would explain the lack of the 
effect of the mAb.   However, it would be then necessary to assume that the 6-AM formed in the 
brain is sufficient to drive heroin self-administration but not heroin-induced CPP or locomotor 
activity.  This discrepancy is not entirely surprising, given that he underpinnings of self-
administration, locomotor activity, and CPP have been shown to be largely independent  (e.g., Bardo 
and Bevins 2000; Ahmed and Cador 2006; Dietz et al. 2007; Shabat-Simon et al. 2008; Caprioli et al. 
2008; Huston et al. 2013).  In this respects, it is important to point out that although the mAb used 
here has very low affinity for heroin (Bogen et al., 2014; Kvello et al., 2016) a higher dose of the mAb 
(Kvello et al., Submitted) might have been effective.  
Alternatively, it is possible that the reinforcing effect sustaining heroin self-administration is 
mediated by other active metabolites of heroin.  Heroin has been considered to be only an effective 
vehicle to deliver morphine to the brain. However, the euphorigenic effect of heroin (the so-called 
‘rush’ or ‘high’) develops very rapidly after systemic administration (Smith and Beecher, 1962), 
  
whereas morphine concentrations in the plasma increase much more slowly (Rook et al., 2006a; 
Rook et al., 2006b), and, owing to its low lipophilicity, even more slowly in the brain, (Gottas et al., 
2014; Seleman et al., 2014).  This explains why higher doses of morphine than of heroin, are 
necessary to produce comparable behavioral responses (Andersen et al., 2009; Bardo et al., 1995; 
Eriksen et al., 2014; Hubner and Kornetsky, 1992; Hutto and Crowder, 1997), and in particular to 
sustain self-administration (Walker et al., 1999). Besides, the levels of morphine reached in the brain 
after systemic heroin administration are not enough to achieve an equivalent behavioral response as 
the one induced by heroin (Andersen et al., 2009). Another candidate for mediating the effects of 
heroin is morphine-6-glucuronide (M6G) (Vindenes et al., 2006; Vindenes et al., 2008). Although very 
little M6G is formed after heroin administration to drug-naïve rats, increased synthesis is observed 
after repeated exposure to heroin (Antonilli et al., 2003, 2005) as well as after heroin-self-
administration (Meringolo et al., 2012).  Yet, the time-course of M6G formation is even more delayed 
than that of morphine, making it less likely that it could significantly contribute to the rapid onset of 
heroin rewarding effects.  
Finally, it is possible that the pharmacodynamics properties of heroin cannot be reduced to that of its 
metabolites.  While heroin has lower affinity for MOP receptors than 6-AM or morphine (Inturrisi et 
al., 1983), its efficacy is similar to 6-AM and greater than morphine (Selley et al., 2001).  Heroin and 
its metabolites differ not only in terms of receptor affinity and efficacy but also in their ability to 
enhance dopamine release in the striatum.  Indeed, Gottas and colleagues (2014) have shown that 
the temporal and quantitative pattern of dopamine release after systemic 6-AM is very different not 
only from that of heroin but also from that of morphine.  On the one hand, the differences in the 
ability to increase dopaminergic transmission, which is thought to play a major role in motivation 
(Berke 2018), might be invoked to explain the differences in the reinforcing effects of 6-AM relative 
to heroin.  On the other hand, it is not easy to explain the mechanisms responsible for these 
differences if the mechanisms of actions of heroin and of its metabolites are the same.  Thus, it is 
possible that the intrinsic reinforcing effects of heroin, 6-AM, morphine, and M6G are mediated at 
least in part by distinct substrates.  For example, since there is evidence that heroin self-
administration is largely independent of striatal dopamine release (for a review, see Badiani et al., 
2011), it would be important to determine if the same is true for 6-AM. 
 
5. CONCLUSION  
The present study shows that the heroin metabolite 6-AM is able to sustain self-administration 
behavior in the rat at a higher rate than equimolar doses of heroin.  However, contrary to our 
working hypothesis, a 6-AM specific monoclonal antibody failed to affect heroin-induced relapse into 
drug-seeking and the re-acquisition of heroin self-administration after a period of relapse.  It is 
possible that heroin deacetylation in the brain yielded sufficient 6-AM (out of the reach of mAb) to 
sustain self-administration.  These findings indicate that more studies are required to clarify if and to 
what extent the reinforcing effects of heroin depend, as commonly held, on its metabolites.   
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Figure 1. Time line of the experimental protocol used through the self-administration study.  
Figure 2. Number (mean ±s.e.m.) of lever presses (upper panel) at the active (circles) or inactive 
(triangles) lever and infusions (lower panel, circles) during the acquisition and extinction of self-
administration of 0.135 µmol/kg 6-AM (filled symbols) or heroin (open symbols). A FR1 schedule was 
used during the first five sessions of acquisition, and a FR2 schedule for the rest of the experiment 
(see Material and Methods for further detail). 
Figure 3. Number (mean ± s.e.m.) of active lever presses (upper panel) and infusions (lower panel) 
during the first hour of the last extinction session (black columns) and the relapse session (grey 
columns). After the last extinction session, animals were treated ip with saline or 10 mg/kg of a 
monoclonal antibody against 6-AM (6-AM mAb). At the start of the relapse session, the animals were 
primed with a single infusion of 0.068 µmol/kg 6-AM or heroin. *p<0.05 versus last extinction session 
(post-hoc paired Student’s t-tests).  
Figure 4. Number (mean ± s.e.m.) of active lever presses (upper panel) and infusions (lower panel) 
during the last acquisition session, last extinction session, and the first re-acquisition session. After 
the last extinction session, animals were administered ip either with saline or 10 mg/kg of a 
monoclonal antibody against 6-AM (6-AM mAb). During the re-acquisition session, the animals self-
administered 0.068 or 0.135 µmol/kg 6-AM or heroin. Whereas the columns for last day of 
acquisition and extinction represent data for all the animals together, two columns are used to 
represent data from animals pretreated with saline or 6-AM antibody. *p<0.05 versus Last Day 
Extinction (post-hoc paired Student’s t-tests); # p<0.05 versus Last Day Acquisition (post-hoc paired 
Student’s t-tests); ¤ p<0.05 versus 0.068 µmol/kg (post-hoc independent Student’s t-tests); & p<0.05 
versus re-acquisition Saline (post-hoc independent Student’s t-tests). 
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